Screener
Oruka Therapeutics, Inc. ORKA EPS (Diluted)
Discontinued — last reported Q2 '25
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed August 11, 2025.
- Filed
- Aug 11, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001213900-25-074281
| Line item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Period from February 6, 2024 (Inception) to June 30, 2024 |
|---|---|---|---|---|
| Total other income (expense), net | 3,855 | (750) | 7,942 | (964) |
| Net loss | (24,574) | (22,243) | (45,573) | (29,320) |
| Net change in unrealized gains (losses) on marketable securities | (21) | — | 14 | — |
| Comprehensive loss | $(24,595) | $(22,243) | $(45,559) | $(29,320) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.46) | $(6.96) | $(0.85) | $(9.17) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(38.26) | — | $(71.23) | — |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 42,095,951 | 3,197,975 | 41,888,906 | 3,197,975 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | — | 137,138 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s EPS (diluted)?
- Oruka Therapeutics, Inc. (ORKA) reported EPS (diluted) of -$0.46 in Q2 2025.
- How has Oruka Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Oruka Therapeutics, Inc.'s EPS (diluted) increased by 93.4% year-over-year, from -$6.96 to -$0.46.
- What is the long-term trend for Oruka Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2024), Oruka Therapeutics, Inc.'s EPS (diluted) has grown at a 118.0% compound annual growth rate (CAGR), from -$1.40 to -$14.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Oruka Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude